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Cost and Patency Rate
Targets for the Development
of Endovascular Devices
to Treat Femoropopliteal
Arterial Disease1
PURPOSE: To determine the criteria that would make use of an endovascular device
cost-effective compared with bypass surgery and percutaneous transluminal angio-
plasty in the treatment of femoropopliteal arterial disease.
MATERIALS AND METHODS: A decision model was developed to compare treat-
ment with the use of a hypothetical endovascular device with established therapies.
Cost-effectiveness from the perspective of the health care system was considered.
Outcome measures were lifetime costs and quality-adjusted life-years. With the use
of net health benefit calculations and threshold analysis, combinations of costs and
patency rates were determined that would make the device cost-effective compared
with established therapies. In subgroup and sensitivity analyses, the effect on
decision-making of sex, age, indication, lesion type, procedural risk, and society’s
willingness to pay for incremental gain in health were explored.
RESULTS: Use of a device that costs $3,000 would be cost-effective compared with
bypass surgery for critical ischemia if the 5-year patency rate is 29%–46%. Use of
the same device would be cost-effective compared with angioplasty for disabling
claudication and stenosis if the 5-year patency rate is 69%–86%.
CONCLUSION: The target combinations of costs and patency rates found in this
study are probably attainable, and further development of such endovascular de-
vices seems warranted.
Although bypass surgery and percutaneous transluminal angioplasty (PTA) are commonly
used revascularization procedures in the treatment of femoropopliteal arterial occlusive
disease, both procedures have disadvantages (1). Percutaneous transluminal balloon an-
gioplasty is a low-risk and low-cost procedure, but it is associated with a fairly high
restenosis rate (2–5). Primary stent placement does not improve the patency rate of PTA
performed for femoropopliteal arterial disease and is thus currently used only to salvage a
failed balloon angioplasty procedure (6,7). Bypass surgery, on the other hand, has higher
long-term patency rates but is also associated with a higher procedural risk, higher cost,
and longer convalescence period (4,5). In general, PTA is performed as primary treatment
of short focal lesions of the femoropopliteal artery, whereas bypass surgery is the primary
treatment in diffuse disease.
Endovascular devices are currently being developed as alternative interventions to
overcome the problems of established procedures. Important considerations in choosing
the optimal treatment strategy are the effectiveness of the device, the risks of the proce-
dures, and the costs. These parameters are generally unknown during the development of
a new technology. In particular, the patency and cost estimates associated with endovas-
cular devices are uncertain and may even change with time. It is difficult, if not impossible,
to predict what the precise values for the parameters of a new technology will be. Given
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the outcome and cost of established pro-
cedures, however, we can calculate under
what conditions a new technology can
become cost-effective compared with the
established procedures, thereby setting
standards for the new device. The merit
of such an approach is that it can poten-
tially focus the development of new tech-
nology (8,9). This applies not only to
femoropopliteal interventions but also to
many other procedures such as the use of
an abdominal aortic endoprosthesis and
placement of a carotid stent.
The purpose of this study was to deter-
mine the criteria that would make the
use of an endovascular device for the
treatment of femoropopliteal arterial dis-
ease cost-effective compared with PTA
and bypass surgery. A secondary objec-
tive was to illustrate how decision and
cost-effectiveness analysis can be used to
focus the development of new technolo-
gies.
MATERIALS AND METHODS
Overview Decision Model
Previously, a decision analytic model
was developed to examine the choice be-
tween bypass surgery and PTA for femo-
ropopliteal arterial occlusive disease (10).
The model was used to consider different
types of patients (age, sex, other risk fac-
tors), varying severity of disease (dis-
abling claudication, rest pain, tissue loss),
and different types of lesions (stenosis,
occlusion) and to combine literature data
on risks, benefits, and costs. The main
outcome measures were quality-adjusted
life expectancy and lifetime cost for each
strategy, depending on patient character-
istics, clinical indication, and lesion type.
In the current study, another treat-
ment option was added to the model,
namely, treatment with a hypothetical
endovascular device. We compared three
treatment strategies. Each strategy al-
lowed at most two treatments. Initial re-
vascularization was accomplished with
balloon angioplasty, with autologous sa-
phenous vein bypass surgery, or use of
the hypothetical endovascular device.
Secondary treatment for primary failure
was undertaken with bypass surgery if
the initial treatment was angioplasty or
use of the endovascular device or with
surgical revision if the initial treatment
was bypass surgery.
Because the procedural risk, cost, and
patency curves of the endovascular de-
vice are unknown, the following assump-
tions were made. The patency curve of
the endovascular device was assumed to
relate, through a proportional hazards
model, to that of PTA, which implies that
the curves of the endovascular device
and of PTA were similar in shape but
different in height. The 5-year patency
rate was used as a measure for the height
of the patency curve. The risk and com-
plications of an endovascular device and
the procedural cost, excluding the cost of
the device itself, will ideally be approxi-
mately the same as those of PTA or lower.
However, since the procedural risk of a
hypothetical device is unknown, we as-
sumed that the morbidity, mortality, and
convalescence period associated with an
endovascular device would be 1.5 times
higher than that of PTA. The procedural
cost of the device (excluding that of the
device itself) was assumed to be approxi-
mately the same as that of PTA.
Threshold analysis was performed to
determine criteria (ie, combinations of
5-year patency rates and costs) that would
make the device equivalent in terms of
cost-effectiveness compared with bypass
surgery and PTA. The model was devel-
oped from the perspective of the health
care system. All costs were adjusted to
1999 U.S. dollars with the use of the med-
ical care–specific consumer price index.
Data and Data Sources
Estimates of procedural mortality,
morbidity, amputation rate, quality-of-
life adjustments, costs, and patency rates
following femoropopliteal PTA and by-
pass surgery were based on findings from
a published meta-analysis and decision
analysis (4,10). The meta-analysis in-
volved a combination of literature data
published between 1985 and 1993 and
pooled patency results following bypass
surgery and PTA for the treatment of fem-
oropopliteal arterial disease, with the use
of a method based on the proportional
hazards model and the actuarial life-table
approach (4). The decision analysis in-
volved a combination of literature data
published in 1995 and earlier and an ex-
amination of the choice between bypass
surgery and PTA for femoropopliteal ar-
terial disease (10).
Table 1 presents the data on bypass
surgery and PTA incorporated in the
model. The costs for angioplasty and by-
pass procedures, physician services, non-
invasive testing during outpatient fol-
low-up, amputation plus rehabilitation,
and annual costs of treatment after an
amputation or with major morbidity
were based on published and unpub-
lished data on charges from the Brigham
and Women’s Hospital Vascular Service
(10,11). All data on charges were adjusted
with the use of cost-to-charge ratios spec-
ified by the cost center and the fiscal year.
Quality-of-life adjustments were based
on the experience of two vascular sur-
geons, two interventional radiologists
(including M.G.M.H.), and an internist
who estimated the various health states
related to peripheral arterial disease with
the use of an abbreviated form of the
Health Utilities Index. This index is used
to rate physical function, role function,
social and emotional well-being, and
general health (10).
The amputation rate following revas-
cularization was assumed to depend on
the initial symptomatic status. Each year,
on average, 1.2% of patients with claudi-
cation, 2.3% of patients with rest pain,
and 6.4% of patients with tissue loss un-
derwent amputation (12,13). Of these pa-
TABLE 1
Data on Currently Used Femoropopliteal Revascularization Procedures
Parameter Bypass Surgery Angioplasty
Procedural mortality (%)
Claudication 0.8 0.2
Critical ischemia 4.7 3.2
Procedural nonfatal systemic morbidity (%) 8.5 1.3
Time lost due to convalescence (d) 7 2
Procedural cost*
Claudication 20,531 10,168
Critical ischemia 25,881 18,171
Primary patency, 1-y/5-y (%)
Claudication and stenosis 91/80 79/68
Claudication and occlusion 91/80 53/35
Critical ischemia and stenosis 84/66 62/47
Critical ischemia and occlusion 84/66 28/12
* In 1999 U.S. dollars. Costs are from the perspective of the health care system and include
materials used, personnel, equipment, administration, overhead, professional fees, and room and
board. The cost of surgical revision of a bypass was assumed to be in the same order of magnitude
as that of primary bypass surgery.
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tients, an estimated 11.5% did not sur-
vive the amputation, and another 38%
experienced major morbidity (14–16).
The convalescence period following am-
putation was approximately 82 days (16).
The total cost of amputation, includ-
ing cost of rehabilitation, was estimated
to be $34,384 (17,18). Follow-up of pa-
tients after revascularization cost, on av-
erage, $543 in the 1st year, $182 annually
thereafter if the artery or bypass re-
mained patent, and $543 annually if fail-
ure occurred (10). The annual cost of
long-term care and treatment in patients
who underwent amputation of a lower
limb was estimated to be $48,877 per
year (17,19–21). The cost of care and
treatment of patients with major morbid-
ity following revascularization or ampu-
tation was estimated to be $11,947 (22).
The relative risk of overall mortality of
patients with peripheral arterial disease
was estimated to be 3.1 compared with
that of the general population matched
for age and sex (12,23). In view of the
recommendations of the Panel on Cost-
effectiveness in Health and Medicine
(24), both costs and benefits were dis-
counted at a rate of 3%.
Determination of Criteria and
Threshold Analysis
A strategy was considered cost-effec-
tive compared with another if the gain in
quality-adjusted life-years (QALYs) justi-
fied the additional monetary costs. The
trade-off between QALYs and additional
monetary cost was considered justified if
it did not exceed society’s maximum
willingness to pay for an incremental
gain of 1 QALY.
To facilitate the calculation of the
threshold values for patency and cost,
the net health benefit (NHB) approach
was used to compare the use of the hy-
pothetical endovascular device with cur-
rently used interventional strategies (25).
The NHB is used to combine costs,
QALYs, and an estimate of society’s will-
ingness to pay, l, for an incremental gain
of 1 QALY in one expression. For each
strategy, we computed the NHB with the
use of the equation NHB 5 QALYs 2
costs/l (25). Two strategies were consid-
ered equivalent in terms of cost-effective-
ness if they yielded the same NHB.
The NHB makes a trade-off between
QALYs gained and monetary expense. In
essence, the use of the NHB is the same as
the use of incremental cost-effectiveness
ratios, but technically, the use of NHB is
more practical. The difference between
the use of the NHB approach and the
incremental cost-effectiveness ratio ap-
proach is that in the use of incremental
cost-effectiveness ratios, society’s willing-
ness to pay can be considered after the
results are obtained, whereas in the use of
the NHB approach, an estimate of soci-
ety’s willingness to pay must be incorpo-
rated in the calculation. For a given esti-
mate of society’s willingness to pay,
however, the conclusions with the use of
either method will be the same. To esti-
mate the effect of the chosen willingness-
to-pay value, one can repeat the analysis
for a range of values. Published estimates
(25) for willingness to pay range from
$20,000 to $100,000 per QALY gained,
and we therefore considered this range in
our calculations.
Baseline and Sensitivity Analysis
The baseline case used in the analysis
was that of a 65-year-old man with fem-
oropopliteal arterial disease without co-
morbidity or other risk factors. In our
baseline analysis, we assumed society’s
willingness to pay to be $20,000 per
QALY gained. In the subgroup analysis,
we explored the effect of disease severity
(disabling claudication, rest pain, tissue
loss) and lesion type (stenosis, occlu-
sion).
In a one-way sensitivity analysis, we
explored the effect of varying age (55 and
75 years), sex, society’s willingness to pay
for the gain of 1 QALY ($50,000 and
$100,000), and the discount rate (2% and
5%) on our results. Furthermore, we per-
formed one-way sensitivity analyses to
explore the effect of a lower and higher
(one and two times that of PTA) proce-
dural risk of the device, including mor-
bidity, mortality, and time lost due to the
intervention. We assumed that the mor-
bidity, mortality, and time lost due to the
intervention of the endovascular device
would not exceed that of bypass surgery.
Finally, we explored the effect of varying
age, sex, society’s willingness to pay, and
procedural risk simultaneously in a four-
way sensitivity analysis.
RESULTS
Whereas bypass surgery yielded the high-
est NHB (Table 2) in patients with
chronic critical ischemia (rest pain or tis-
sue loss) and a femoropopliteal occlu-
sion, PTA yielded the highest NHB in ste-
notic femoropopliteal lesions irrespective
of the clinical indication. The Figure pre-
sents the target values that would make
the use of an endovascular device cost-
effective compared with currently used
procedures. For example, the Figure, part
a, shows that an endovascular device that
costs $2,500 and that is associated with a
5-year patency rate of 80% would be cost-
effective compared with PTA for the
treatment of a femoropopliteal stenosis,
independent of the clinical indication.
However, an endovascular device with
the same long-term patency but with a
cost of $7,500 would not be cost-effective
compared with PTA for the treatment of a
stenosis and claudication, whereas it
would be cost-effective for the treatment
of a stenosis and critical ischemia. The
Figure, part b, shows that the lines are
TABLE 2
Health Effects, Costs, and NHB of Currently Available Therapies for
Femoropopliteal Arterial Disease
Indication and Lesion
Initial
Treatment
QALE
(QALY)
Cost
($)
NHB (QALY
equivalents)
Claudication
Stenosis PTA 5.85 22,758 4.71
Stenosis Bypass 5.46 33,229 3.80
Occlusion PTA 5.59 32,131 3.99
Occlusion Bypass 5.46 33,229 3.80
Rest pain
Stenosis PTA 5.26 42,372 3.14
Stenosis Bypass 5.00 44,694 2.76
Occlusion PTA 4.83 55,074 2.08
Occlusion Bypass 5.00 44,694 2.76
Tissue loss
Stenosis PTA 5.20 48,589 2.77
Stenosis Bypass 4.92 53,346 2.25
Occlusion PTA 4.74 65,578 1.46
Occlusion Bypass 4.92 53,346 2.25
Note.—QALE 5 quality-adjusted life expectancy. All costs are from the perspective of the health
care system and include hospital and physician costs for the initial and secondary procedures,
treatment of complications, follow-up, long-term care, and amputation and rehabilitation.
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more to the left compared with those in
part a, which implies that for the treat-
ment of occlusions, the target 5-year pa-
tency rates are less stringent.
By considering the treatment of critical
ischemia and an occlusion, the graphs
show that for any given cost of the endo-
vascular device, the patency rates needed
to make use of the device cost-effective
compared with bypass surgery (Fig 1, part
c) were higher than those required to
make the device cost-effective compared
with PTA (Figure, part b). This is consis-
tent with the findings presented in Table
2, which shows that bypass surgery
yielded a higher NHB than PTA in the
treatment of critical ischemia and occlu-
sion.
A striking finding was the high accept-
able cost for an endovascular device, pro-
vided that it is associated with a high
long-term patency rate. For example, the
Figure, part c, shows that, if an endovas-
cular device has a 5-year patency rate of
80%, the cost of the device may increase
to $20,000, and it would still be cost-
effective compared with bypass surgery,
irrespective of the clinical indication.
The results are shown in more detail in
Table 3 for two endovascular devices, one
device that costs $3,000 and a second de-
vice that costs $6,000. For clarity, rest pain
and tissue loss were replaced by critical
ischemia to take into account the highest
patency rate required. Table 3 shows the
5-year patency rates and the associated
1-year patency rates that would make an
endovascular device equivalent in terms of
cost-effectiveness compared with currently
used procedures. For example, the 5-year
patency rate that would make a device that
costs $3,000 cost-effective compared with
bypass surgery for the treatment of critical
ischemia was 43% in the baseline analysis.
Results of one-way sensitivity analyses
demonstrated that with an increase in
society’s willingness to pay, female sex,
and a younger age, lower patency rates
would be acceptable for an endovascular
device. A higher procedural risk and a
higher age increased the required pa-
tency rates. The tabulated ranges (Table
3) indicate the lowest and highest re-
quired patency rates found when age,
sex, procedural risk, and society’s willing-
ness to pay were simultaneously varied in
a sensitivity analysis. Variation of the dis-
count rate from 2% to 5% in one-way
sensitivity analyses resulted in an abso-
lute difference of, at most, 1% when
these rates were compared with the
5-year patency rates found in the base-
line analyses.
DISCUSSION
We report target values of primary pa-
tency rates and costs that a hypothetical
endovascular device for the treatment of
femoropopliteal arterial disease would
have to attain to be cost-effective com-
pared with currently used therapies. The
results help predict under what condi-
tions an endovascular device would be
the most promising and can help focus
future technologic development of endo-
vascular devices. As previously demon-
strated (10), the results illustrate that
when currently used procedures are con-
sidered, PTA is more cost-effective com-
pared with bypass surgery in the treat-
ment of milder forms of femoropopliteal
arterial disease, and bypass surgery is the
TABLE 3
Primary Patency Rates Required to Make an Endovascular Device Equivalent to
Currently Available Treatments in Terms of Cost-Effectiveness
Procedure and Indication
Patency with $3,000 Device Patency with $6,000 Device
One Year Five Year One Year Five Year
Bypass surgery
Claudication 53 (41–57) 37 (25–41) 59 (44–64) 44 (28–49)
Critical ischemia 58 (45–61) 43 (29–46) 63 (47–68) 48 (31–54)
PTA for occlusion
Claudication 60 (53–65) 45 (36–51) 66 (54–73) 52 (38–61)
Critical ischemia 36 (28–39) 20 (13–22) 42 (29–46) 25 (14–29)
PTA for stenosis
Claudication 85 (79–91) 77 (69–86) 89 (80–98) 84 (70–96)
Critical ischemia 69 (61–72) 55 (46–60) 72 (62–78) 60 (47–67)
Note.—Patency rates were determined at baseline analysis. Numbers in parentheses represent the
range of patency rates found after performing a four-way sensitivity analysis with simultaneously
varying sex, age (55, 65, and 75 years), society’s willingness to pay ($20,000, $50,000, and
$100,000 per QALY), and procedural risk of the new device (1, 1.5, and 2 times that of PTA).
Target values that would make an endovascular device cost-effective compared with (a) angioplasty for a stenosis, (b) angioplasty for occlusions,
and (c) bypass surgery. The x axis represents hypothetical 5-year patency rates of the endovascular device; the y axis, hypothetical costs. Lines
represent combinations of 5-year patency rates and costs that would make the endovascular device equivalent to the therapy to which it is being
compared in terms of cost-effectiveness, depending on clinical indication: tissue loss (), rest pain (u), and claudication (E). Area below the lines
represents the target combinations of patency rates and costs that would make the device (ND) more cost-effective than the therapy to which it is
being compared. Area above the lines represents combinations that would make either bypass surgery (BS) or angioplasty (PTA) more cost-effective.
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treatment of choice in more severe dis-
ease.
When an endovascular device is con-
sidered, the results suggest that the target
5-year primary patency rate that would
make a device that costs $3,000 equiva-
lent in terms of cost-effectiveness com-
pared with bypass surgery ranges from
25% to 46%. The 5-year patency rates
that would make a device that costs
$3,000 equivalent in terms of cost-effec-
tiveness compared with PTA in the treat-
ment of claudication and femoropopli-
teal stenosis ranged from 69% to 86%.
Furthermore, the results suggest that use
of a hypothetical endovascular device,
with a 5-year patency rate of 80%, would
be cost-effective compared with bypass
surgery, even if the device costs up to
$20,000, irrespective of clinical indica-
tion.
Caution should be exercised when
conclusions are made about cost-effec-
tiveness. Cost-effectiveness is always rel-
ative. In the current study, we compared
treatment with use of an endovascular
device with bypass surgery and with PTA.
If more than one endovascular device
were to be made available on the market,
they would have to be compared with
each other. Thus, an expensive currently
available device may have a cost-effec-
tiveness ratio just below the willingness-
to-pay threshold compared with bypass
surgery or with PTA, whereas in the fu-
ture, that device may no longer be cost-
effective if another device yields nearly
the same effectiveness at a lower cost.
Limitations of the analysis lie within
the assumptions of the model. First, we
did not update the data concerning the
currently used procedures in the model.
Although the patency rates and risks of
both PTA and bypass surgery are contin-
ually improving, a major improvement
in the past 5 years is unlikely (1). There-
fore, we assumed that the data used in
the 1995 model were still valid. Further-
more, there is evidence that the cost of
femoropopliteal revascularization has not
changed considerably during the past
few years (5).
Second, the data on costs associated
with current therapies were collected in a
teaching hospital in the United States.
Caution should be exercised when the
results are generalized to nonteaching
hospitals or hospitals in other countries.
Third, we assumed that the procedural
risk (complications, mortality) of an en-
dovascular device would be 1.5 times
higher than that of PTA. We assumed this
because, ideally, the procedural risk of an
endovascular treatment would be the
same as that of PTA or lower. However, to
make the baseline results also applicable
for an endovascular treatment associated
with less favorable morbidity and mortal-
ity rates, we assumed that the procedural
risk associated with the endovascular de-
vice was 50% higher than that of PTA. In
sensitivity analyses, we explored the ef-
fect of varying the procedural risk and
the convalescence period, ranging from
one to two times that of PTA, and found
that an increase in procedural risk and
convalescence period resulted in more
stringent target values for the endovascu-
lar device.
Fourth, the hypothetical patency curves
of the endovascular device were based on
the patency curve of PTA. By doing this,
we assumed that most failures occur dur-
ing the 1st year after the procedure. We
assumed this because both are endovas-
cular treatments, but the true curve is
unknown.
Fifth, the choice of the threshold value
of society’s willingness to pay may have
been a limitation. Estimates of society’s
willingness to pay are highly dependent
on the societal and decision context (26).
In the baseline analyses of the current
study, we assumed society’s willingness
to pay to be $20,000 per QALY gained,
and we explored the influence of choos-
ing a threshold of $50,000 per QALY
gained and that of $100,000 per QALY
gained on our results. Because we chose a
higher threshold, which implies the accep-
tance of higher costs for the same health
effect, the results yielded less stringent
criteria for the hypothetical endovascular
device.
Current research on endovascular de-
vices to treat femoropopliteal arterial dis-
ease focuses on the problem of intimal
hyperplasia, which causes secondary ob-
struction after an angioplasty procedure
or stent implantation. The idea is to pre-
vent secondary obstruction by covering
the arterial wall with prosthetic material,
such as polytetrafluoroethylene, now of-
ten used as the conduit material in by-
pass surgery. Primary patency rates re-
ported (27-29) thus far associated with
such stent-grafts range from 73% at 12
months to 59% at 18 months to 46% at
24 months. One group of investigators
(30) recently reported less favorable re-
sults (12-month patency rate, 29%). The
results in the current analysis suggest
that the target 12-month primary pa-
tency rate for an endovascular device
that costs $3,000 is approximately 41%–
61%. This finding suggests that, if the
assumptions in this study hold true, the
use of these devices may already be cost-
effective compared with bypass surgery.
The validity and generalizability of the
reported patency rates in these initial
studies were, however, low because the
sample sizes were limited and because
data on long-term results were not avail-
able.
The methods used in this study can be
applied to many situations where investi-
gators are developing therapeutic technol-
ogies. Other examples of new technologies
under development are endovascular de-
vices for the treatment of abdominal aortic
aneurysms and catheter techniques with
the use of coiling devices for the treatment
of cerebral aneurysms. Perhaps the first
step in investigations of new technologies,
both therapeutic and diagnostic, should be
to establish clear-cut goals for the perfor-
mance of such technologies compared
with existing ones. Such analyses could
help focus research and the development
of new technologies and thereby help to
save valuable resources (8,9).
In conclusion, the results of this cost-
effectiveness analysis in which target cost
and patency rates were estimated demon-
strate that there is a place for a new en-
dovascular therapy in the treatment of
femoropopliteal arterial disease. The tar-
get values of patency rates and costs de-
termined in this study that would make
the use of an endovascular device cost-
effective compared with the currently
used therapies are probably attainable,
and further development of endovascu-
lar devices seems warranted.
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